title: Small molecules showing significant protection of mice against botulinum neurotoxin serotype A.
abstract: Botulinum neurotoxin serotype A (BoNTA) causes a life-threatening neuroparalytic disease known as botulism that could afflict large, unprotected populations if the toxin were employed in an act of bioterrorism. Current post-exposure therapy is limited to symptomatic treatment or passive immunization that is effective for treating infant botulism at a cost of US $45,300 per treatment regimen. Antibodies can neutralize the extracellular but not the intracellular BoNTA. Moreover, antibody production, storage, and administration in a mass casualty scenario pose logistical challenges. Alternatively, small-molecule inhibitors of BoNTA endopeptidase (BoNTAe) are sought to antagonize the extracellular or intracellular toxin. While several such molecules reportedly demonstrated efficacy in protecting cells against BoNTA, there is scant information to show that small molecules can significantly protect mammals against BoNTA. Herein we report the development of effective small-molecules BoNTAe inhibitors with promising in vivo pharmacokinetics. One such molecule has an in vivo half-life of 6.5 hours and is devoid of obvious sign of toxicity. Pre-treatment with this molecule at 2 mg/kg protected 100% and 70% of treated mice against BoNTA at 5 times of its median-lethal dose during the periods of 2 and 4 half-lives of the inhibitor, respectively. In contrast, 40% and 0% of untreated mice survived during the respective periods. Similar levels of protection were also observed with two other small molecules. These results demonstrate that small molecules can significantly protect mice against BoNTA and support the pursuit of small-molecule antagonists as a cost-effective alternative or as an adjunct to passive immunity for treating botulism.
authors.affiliation: Computer-Aided Molecular Design Laboratory, Mayo Clinic, Rochester, Minnesota, United States of America. pang@mayo.edu
authors.forename: Yuan-Ping
authors.initials: YP
authors.lastname: Pang
authors.forename: Jon
authors.initials: J
authors.lastname: Davis
authors.forename: Shaohua
authors.initials: S
authors.lastname: Wang
authors.forename: Jewn Giew
authors.initials: JG
authors.lastname: Park
authors.forename: Madhusoodana P
authors.initials: MP
authors.lastname: Nambiar
authors.forename: James J
authors.initials: JJ
authors.lastname: Schmidt
authors.forename: Charles B
authors.initials: CB
authors.lastname: Millard
mesh_terms: D000818:Animals; D023482:Bioterrorism; D019274:Botulinum Toxins, Type A / Q000037:antagonists & inhibitors*; D003365:Costs and Cost Analysis; D051379:Mice; D009498:Neurotoxins; D011480:Protease Inhibitors / Q000191:economics / Q000493:pharmacokinetics* / Q000627:therapeutic use; D020011:Protective Agents; D015996:Survival Rate
chemical_list: D009498:Neurotoxins; D011480:Protease Inhibitors; D020011:Protective Agents; D019274:Botulinum Toxins, Type A
references.citation: J Infect Dis. 1984 Sep;150(3):407-12
references.pmid: 6481185
references.citation: Toxicon. 2010 Apr 1;55(4):818-26
references.pmid: 20003913
references.citation: Am J Law Med. 2006;32(2-3):279-323
references.pmid: 16927613
references.citation: Clin Neuropharmacol. 2007 Sep-Oct;30(5):310-3
references.pmid: 17909312
references.citation: PLoS One. 2007 Aug 22;2(8):e761
references.pmid: 17712409
references.citation: JAMA. 2001 Feb 28;285(8):1059-70
references.pmid: 11209178
references.citation: Biophys J. 2009 Aug 5;97(3):853-6
references.pmid: 19651043
references.citation: Proteins. 2006 Nov 15;65(3):712-25
references.pmid: 16981200
references.citation: Ann Intern Med. 1998 Aug 1;129(3):221-8
references.pmid: 9696731
references.citation: J Biol Chem. 2007 Feb 16;282(7):5004-5014
references.pmid: 17092934
references.citation: Bioorg Med Chem. 2006 Jan 15;14(2):395-408
references.pmid: 16203152
references.citation: J Comput Chem. 2005 Dec;26(16):1668-88
references.pmid: 16200636
references.citation: Proteins. 2001 Nov 15;45(3):183-9
references.pmid: 11599021
references.citation: PLoS One. 2009 Nov 10;4(11):e7730
references.pmid: 19901994
references.citation: Biochemistry. 2008 May 27;47(21):5736-45
references.pmid: 18457419
references.citation: Bioorg Med Chem. 2009 Apr 15;17(8):3072-9
references.pmid: 19329331
references.citation: Protein Sci. 2000 Oct;9(10):1857-65
references.pmid: 11106157
references.citation: J Clin Immunol. 1993 Mar;13(2):145-51
references.pmid: 8320311
references.citation: Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9984-9
references.pmid: 15985558
references.citation: FEBS Lett. 1998 Sep 11;435(1):61-4
references.pmid: 9755859
references.citation: J Chem Theory Comput. 2007 Nov;3(6):2312-34
references.pmid: 26636222
references.citation: Neurotoxicology. 1997;18(3):761-70
references.pmid: 9339823
references.citation: Chem Biol Drug Des. 2008 Feb;71(2):131-9
references.pmid: 18221310
references.citation: Pediatrics. 2007 Apr;119(4):785-9
references.pmid: 17403850
references.citation: Chem Commun (Camb). 2006 Aug 7;(29):3063-5
references.pmid: 16855686
references.citation: Antimicrob Agents Chemother. 2009 Aug;53(8):3478-86
references.pmid: 19528275
references.citation: JAMA. 1997 Aug 6;278(5):399-411
references.pmid: 9244332
references.citation: Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2602-7
references.pmid: 17293454
references.citation: JAMA. 2009 Jun 10;301(22):2316
references.pmid: 19509371
references.citation: Nature. 2004 Dec 16;432(7019):925-9
references.pmid: 15592454
references.citation: J Protein Chem. 1997 Jan;16(1):19-26
references.pmid: 9055204
references.citation: Science. 2007 Sep 28;317(5846):1881-6
references.pmid: 17901324
references.citation: Pharmacol Rev. 1981 Sep;33(3):155-88
references.pmid: 6119708
references.citation: J Biol Chem. 2003 Jan 10;278(2):1363-71
references.pmid: 12381720